In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …
It’s a very rewarding trading day for investors in Trevena (TRVN) with shares up over 70%, making the stock Wall Street’s bull of …
Amarin (AMRN) has had a lot of attention over its fish oil pill Vascepa, which aims to help those with cardiovascular problems and …
Aphria (APHA) stock tests investor nerves in roller coaster ride following an announcement Thursday from U.S.
Canadian pharmaceutical company Tilray (TLRY) announced this week a partnership with beer and beverage giant Anheuser-Busch InBev to research cannabis beverages. The two companies will be investing …
Medical cannabis maker Tilray (TLRY) announced early Tuesday that it has entered into a global supply and distribution agreement for medical marijuana with …
It’s a new age, alright. Cannabis is becoming more normalized and companies are already capitalizing.
As Bausch Health (BHC) attempts to swallow up bankrupt Synergy Pharmaceuticals (SGYP), Seeking Alpha blogger Biotech Spectator (BS) says Synergy’s beloved Irritable Bowel …
In a dramatic change, Trump announced on Friday that marijuana reform ally Mick Mulvaney will replace marijuana opponent John Kelly as his acting …
Blogger Christiana Friedman says the FDA decision for Amarin’s (AMRN) drug Vascepa might not be the make or break for the company. In …
